US start-up Cardeus acquires three Astellas molecules
This article was originally published in Scrip
Executive Summary
Astellas has licensed out the ex-Japan global rights to three of its pipeline compounds to the US start-up Cardeus Pharmaceuticals, in a deal that could see the Japanese major re-acquire selected rights in certain markets once Cardeus has moved the projects further through development.